Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review

References

• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019;33(1):128–135. doi:10.1111/jdv.15159
   PubMed Web of Science ®Google Scholar
• Singh P, Silverberg JI. Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis. Arch Dermatol Res. 2021;313(3):163–171. doi:10.1007/s00403-020-02087-w
   PubMed Web of Science ®Google Scholar
• Berna-Rico E, Abbad-Jaime de Aragon C, Garcia-Aparicio A, et al. Cardiovascular screening practices and statin prescription habits in patients with psoriasis among dermatologists, rheumatologists and primary care physicians. Acta Derm Venereol. 2023;103:adv5087. doi:10.2340/actadv.v103.5087
   PubMed Web of Science ®Google Scholar
• Parsi KK, Brezinski EA, Lin TC, Li CS, Armstrong AW. Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. J Am Acad Dermatol. 2012;67(3):357–362. doi:10.1016/j.jaad.2011.09.006
   PubMed Web of Science ®Google Scholar
• Callis Duffin K, Merola JF, Christensen R, et al. Identifying a core domain set to assess psoriasis in clinical trials. JAMA Dermatol. 2018;154(10):1137–1144. doi:10.1001/jamadermatol.2018.1165
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Armstrong AW, et al. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial. JAMA Dermatol. 2022;158(12):1394–1403. doi:10.1001/jamadermatol.2022.3862
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784–93. e2. doi:10.1016/j.jid.2020.01.025
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi:10.1001/jama.296.14.1735
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062. doi:10.1161/JAHA.113.000062
   PubMed Web of Science ®Google Scholar
• Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–2346. doi:10.1038/jid.2013.149
   PubMed Web of Science ®Google Scholar
• Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650–6.e3. doi:10.1016/j.jaad.2017.06.028
   PubMed Web of Science ®Google Scholar
• Mehta NN, Krishnamoorthy P, Yu Y, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67(4):796–798. doi:10.1016/j.jaad.2012.05.016
   PubMed Web of Science ®Google Scholar
• Shen J, Lam SH, Shang Q, et al. Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis. J Rheumatol. 2018;45(2):218–226. doi:10.3899/jrheum.170025
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheumatic Dis. 2014;73(11):1990–1996. doi:10.1136/annrheumdis-2013-203433
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi:10.1016/j.jacc.2018.11.003
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. doi:10.1093/eurheartj/ehw106
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. doi:10.1016/j.jacc.2018.11.002
   PubMed Web of Science ®Google Scholar
• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113. doi:10.1016/j.jaad.2018.11.058
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–1024. doi:10.1016/j.jaad.2013.06.053
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–42; discussion 42–3. doi:10.1097/HJH.0b013e32835bcce1
   Web of Science ®Google Scholar
• Choudhary S, Pradhan D, Pandey A, et al. The association of metabolic syndrome and psoriasis: a systematic review and meta-analysis of observational study. Endocr Metab Immune Disord Drug Targets. 2020;20(5):703–717. doi:10.2174/1871530319666191008170409
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022;45(7):1277–1288. doi:10.1007/s40618-022-01755-0
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cantero A, Teklu M, Sorokin AV, et al. Subclinical liver disease is associated with subclinical atherosclerosis in psoriasis: results from two observational studies. J Invest Dermatol. 2022;142(1):88–96. doi:10.1016/j.jid.2021.05.034
   PubMed Web of Science ®Google Scholar
• Musunuru K, Kathiresan S. Genetics of common, complex coronary artery disease. Cell. 2019;177(1):132–145. doi:10.1016/j.cell.2019.02.015
   PubMed Web of Science ®Google Scholar
• Ye J, Wang Y, Wang Z, et al. Roles and mechanisms of interleukin-12 family members in cardiovascular diseases: opportunities and challenges. Front Pharmacol. 2020;11:129. doi:10.3389/fphar.2020.00129
   PubMed Web of Science ®Google Scholar
• Zhang M, Cai Z-R, Zhang B, et al. Functional polymorphisms in interleukin-23 receptor and susceptibility to coronary artery disease. DNA Cell Biol. 2014;33(12):891–897. doi:10.1089/dna.2014.2573
   PubMed Web of Science ®Google Scholar
• Zhao Q, Jiang H, Ma T, Qiu H, Guo M, Zhang X. The association between IL‐17A and IL‐23R polymorphisms and coronary artery disease risk in a Middle Eastern Chinese population. J Clin Lab Analysis. 2019;33(6):e22893. doi:10.1002/jcla.22893
   PubMed Web of Science ®Google Scholar
• Kave M, Shadman M, Alizadeh A, Samadi M. Analysis of the association between IL‐23R rs11209026 polymorphism and incidence of atherosclerosis. Int J Immunogenet. 2015;42(5):341–345. doi:10.1111/iji.12223
   PubMed Web of Science ®Google Scholar
• Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nature Genet. 2009;41(2):199–204. doi:10.1038/ng.311
   PubMed Web of Science ®Google Scholar
• Chen H, Poon A, Yeung C, et al. A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One. 2011;6(4):e19454. doi:10.1371/journal.pone.0019454
   PubMed Web of Science ®Google Scholar
• Eiris N, Santos-Juanes J, Coto-Segura P, et al. Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes. Cytokine. 2012;60(1):27–29. doi:10.1016/j.cyto.2012.05.030
   PubMed Web of Science ®Google Scholar
• Vázquez-Vázquez C, Posadas-Sánchez R, Pérez-Hernández N, et al. The rs2066808 polymorphism located near the IL-23A gene is associated with premature coronary artery disease in Mexican population (GEA study). DNA Cell Biol. 2019;38(8):880–886. doi:10.1089/dna.2019.4683
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–290. doi:10.1086/511051
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou H. A meta-analysis of the relationship between tumor necrosis factor-α polymorphisms and psoriasis. Dermatology. 2021;237(1):39–45.
   PubMed Web of Science ®Google Scholar
• Huang R, Zhao S-R, Li Y, et al. Association of tumor necrosis factor-α gene polymorphisms and coronary artery disease susceptibility: a systematic review and meta-analysis. BMC Med Genet. 2020;21(1):1–15. doi:10.1186/s12881-020-0952-2
   PubMed Web of Science ®Google Scholar
• Kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-α production in psoriasis patients carrying the TNF-α 238A promoter polymorphism. J Invest Dermatol. 2000;114(6):1180–1183. doi:10.1046/j.1523-1747.2000.00001.x
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Y, Qiu L, Wu J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. BMC Med. 2022;20(1):421. doi:10.1186/s12916-022-02617-5
   PubMed Web of Science ®Google Scholar
• Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315–327. doi:10.1161/CIRCRESAHA.118.313591
   PubMed Web of Science ®Google Scholar
• Zhang K, Li X, Yin G, Liu Y, Tang X. Functional characterization of T cells differentiated in vitro from bone marrow‐derived CD34+ cells of psoriatic patients with family history. Exper Dermatol. 2010;19(8):e128–e35. doi:10.1111/j.1600-0625.2009.01016.x
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Ann Rev Immunol. 2014;32(1):227–255. doi:10.1146/annurev-immunol-032713-120225
   PubMedGoogle Scholar
• Liuzzo G, Vallejo AN, Kopecky SL, et al. Molecular fingerprint of interferon-γ signaling in unstable angina. Circulation. 2001;103(11):1509–1514. doi:10.1161/01.CIR.103.11.1509
   PubMed Web of Science ®Google Scholar
• Methe H, Kim J-O, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4–positive monocytes in patients with acute coronary syndrome. Circulation. 2005;111(20):2654–2661. doi:10.1161/CIRCULATIONAHA.104.498865
   PubMed Web of Science ®Google Scholar
• Takahashi H, Numasaki M, Lotze MT, Sasaki H. Interleukin-17 enhances bFGF-, HGF-and VEGF-induced growth of vascular endothelial cells. Immunol Lett. 2005;98(2):189–193. doi:10.1016/j.imlet.2004.11.012
   PubMed Web of Science ®Google Scholar
• Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett. 2004;93(1):39–43. doi:10.1016/j.imlet.2004.01.014
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Trotta F, Pedicino D. Interleukin-17 in Atherosclerosis and Cardiovascular Disease: The Good, the Bad, and the Unknown. Oxford University Press; 2013:556–559.
   Google Scholar
• Erbel C, Akhavanpoor M, Okuyucu D, et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol. 2014;193(9):4344–4355. doi:10.4049/jimmunol.1400181
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174(1):164–173. doi:10.4049/jimmunol.174.1.164
   PubMed Web of Science ®Google Scholar
• Han S-F, Liu P, Zhang W, et al. The opposite-direction modulation of CD4+ CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol. 2007;124(1):90–97. doi:10.1016/j.clim.2007.03.546
   PubMed Web of Science ®Google Scholar
• Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4+ CD25+ regulatory T cells in patients with acute coronary syndromes. Eur Heart J. 2006;27(21):2530–2537. doi:10.1093/eurheartj/ehl222
   PubMed Web of Science ®Google Scholar
• Rolski F, Błyszczuk P. Complexity of TNF-α signaling in heart disease. J Clin Med. 2020;9(10):3267. doi:10.3390/jcm9103267
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang X, Bian F, et al. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ. J Mol Cell Cardiol. 2014;72:85–94. doi:10.1016/j.yjmcc.2014.02.012
   PubMed Web of Science ®Google Scholar
• Bai F, Zheng W, Dong Y, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9(1):1266. doi:10.18632/oncotarget.22260
   PubMedGoogle Scholar
• Arican O, Aral M, Sasmaz S, Ciragil P. Serum Levels of TNF- α, IFN- γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflammation. 2005;2005(5):273–279. doi:10.1155/MI.2005.273
   PubMed Web of Science ®Google Scholar
• Uyemura K, Demer L, Castle S, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996;97(9):2130–2138. doi:10.1172/JCI118650
   PubMed Web of Science ®Google Scholar
• Allam G, Abdel-Moneim A, Gaber AM. The pleiotropic role of interleukin-17 in atherosclerosis. Biomed Pharmacother. 2018;106:1412–1418. doi:10.1016/j.biopha.2018.07.110
   PubMed Web of Science ®Google Scholar
• Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol. 2011;106(1):125–134. doi:10.1007/s00395-010-0135-y
   PubMed Web of Science ®Google Scholar
• Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arteriosclerosis Thrombosis Vasc Biol. 2015;35(12):2667–2676. doi:10.1161/ATVBAHA.115.306460
   PubMed Web of Science ®Google Scholar
• Frodermann V, Nahrendorf M. Neutrophil–Macrophage Cross-Talk in Acute Myocardial Infarction. Oxford University Press; 2017:198–200.
   Google Scholar
• Zernecke A. Dendritic cells in atherosclerosis: evidence in mice and humans. Arteriosclerosis Thrombosis Vasc Biol. 2015;35(4):763–770. doi:10.1161/ATVBAHA.114.303566
   PubMed Web of Science ®Google Scholar
• Clark RA, Kupper TS. Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest. 2006;116(8):2084–2087. doi:10.1172/JCI29441
   PubMed Web of Science ®Google Scholar
• Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709–721. doi:10.1038/nri3520
   PubMed Web of Science ®Google Scholar
• Rahman K, Vengrenyuk Y, Ramsey SA, et al. Inflammatory Ly6C hi monocytes and their conversion to M2 macrophages drive atherosclerosis regression. J Clin Invest. 2017;127(8):2904–2915. doi:10.1172/JCI75005
   PubMed Web of Science ®Google Scholar
• Sanda G, Belur A, Teague H, Mehta NN. Emerging associations between neutrophils, atherosclerosis, and psoriasis. Curr Atherosclerosis Rep. 2017;19(12):1–8. doi:10.1007/s11883-017-0692-8
   PubMed Web of Science ®Google Scholar
• Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutierrez L, García-Orozco A, Alvarado-Navarro A, Fafutis-Morris M. Neutrophil extracellular traps and its implications in inflammation: an overview. Front Immunol. 2017;8:81. doi:10.3389/fimmu.2017.00081
   PubMed Web of Science ®Google Scholar
• Teague HL, Aksentijevich M, Stansky E, et al. Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. J Invest Dermatol. 2020;140(4):912–5.e1. doi:10.1016/j.jid.2019.07.724
   PubMed Web of Science ®Google Scholar
• Karsulovic C, Loyola K, Cabrera R, Perez C, Hojman L. Non-canonical WNT/Wnt5a pathway activity in circulating monocytes of untreated psoriatic patients: an exploratory study of its association with inflammatory cytokines and cardiovascular risk marker-ADAMTS7. Biomedicines. 2023;11(2):577. doi:10.3390/biomedicines11020577
   PubMed Web of Science ®Google Scholar
• Loyola K, Karsulovic C, Cabrera R, Perez C, Hojman L. New markers for cardiovascular disease in psoriatic patients: preliminary study on monocyte phenotype, ADAMTS7, and mTOR Activity. Metabolites. 2023;13(1):116. doi:10.3390/metabo13010116
   PubMed Web of Science ®Google Scholar
• Takematsu H, Ohkohchi K, Tagami H. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses. Br J Dermatol. 1986;114(1):1–6. doi:10.1111/j.1365-2133.1986.tb02773.x
   PubMed Web of Science ®Google Scholar
• Fleming CJ, Holme ER, Mackie RM. Systemic complement activation in psoriasis vulgaris. Clin Exp Dermatol. 1996;21(6):415–418. doi:10.1111/j.1365-2230.1996.tb00144.x
   PubMed Web of Science ®Google Scholar
• Martínez-López D, Roldan-Montero R, García-Marqués F, et al. Complement C5 protein as a marker of subclinical atherosclerosis. J Am Coll Cardiol. 2020;75(16):1926–1941. doi:10.1016/j.jacc.2020.02.058
   PubMed Web of Science ®Google Scholar
• Mourino-Alvarez L, Perales-Sanchez I, Berna-Rico E, et al. Association of the complement system with subclinical atherosclerosis in psoriasis: findings from an observational cohort study. J Invest Dermatol. 2023;144(5):1075–1087.e2. doi:10.1016/j.jid.2023.10.031
   PubMedGoogle Scholar
• Rose S, Stansky E, Dagur PK, et al. Characterization of immune cells in psoriatic adipose tissue. J Transl Med. 2014;12(1):1–13. doi:10.1186/s12967-014-0258-2
   PubMedGoogle Scholar
• Toussirot E, Aubin F, Desmarets M, et al. Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology. 2021;60(6):2816–2825. doi:10.1093/rheumatology/keaa720
   PubMed Web of Science ®Google Scholar
• Manyak GA, Patel NH, Dey AK, et al. Abdominal visceral adiposity is associated with coronary artery plaque lipid-rich necrotic core partly mediated by bone marrow uptake of (18)F-FDG positron emission tomography/computed tomography in psoriasis. J Invest Dermatol. 2022;142(7):2030–3.e1. doi:10.1016/j.jid.2021.10.031
   PubMed Web of Science ®Google Scholar
• Coimbra S, Catarino C, Santos-Silva A. The triad psoriasis-obesity-adipokine profile. J Eur Acad Dermatol Venereol. 2016;30(11):1876–1885. doi:10.1111/jdv.13701
   PubMed Web of Science ®Google Scholar
• Elnabawi YA, Oikonomou EK, Dey AK, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol. 2019;4(9):885–891. doi:10.1001/jamacardio.2019.2589
   PubMed Web of Science ®Google Scholar
• Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc. 2014;3(2):e000582. doi:10.1161/JAHA.113.000582
   PubMed Web of Science ®Google Scholar
• Słuczanowska-Głabowska S, Staniszewska M, Marchlewicz M, et al. Adiponectin, leptin and resistin in patients with psoriasis. J Clin Med. 2023;12(2):663. doi:10.3390/jcm12020663
   PubMed Web of Science ®Google Scholar
• Schlenker SM, Munhoz SI, Busanello AR, et al. Resistin serum levels and its association with clinical profile and carotid intima-media thickness in psoriasis: a cross-sectional study. An Bras Dermatol. 2023;98(6):799–805. doi:10.1016/j.abd.2022.10.011
   PubMed Web of Science ®Google Scholar
• Packer M. Epicardial adipose tissue inflammation can cause the distinctive pattern of cardiovascular disorders seen in psoriasis. Am J Med. 2020;133(3):267–272. doi:10.1016/j.amjmed.2019.08.027
   PubMed Web of Science ®Google Scholar
• Ellis CN, Neville SJ, Sayyouh M, et al. Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: a cross-sectional study. J Am Acad Dermatol. 2022;86(3):535–543. doi:10.1016/j.jaad.2021.09.069
   PubMed Web of Science ®Google Scholar
• Kaiser H, Kvist-Hansen A, Krakauer M, et al. Association between vascular inflammation and inflammation in adipose tissue, spleen, and bone marrow in patients with psoriasis. Life. 2021;11(4):305. doi:10.3390/life11040305
   PubMedGoogle Scholar
• Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489. doi:10.1136/annrheumdis-2014-206624
   PubMed Web of Science ®Google Scholar
• Hugh J, Van Voorhees AS, Nijhawan RI, et al. From the medical board of the national psoriasis foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014;70(1):168–177. doi:10.1016/j.jaad.2013.09.020
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250. doi:10.1001/archdermatol.2012.2502
   PubMed Web of Science ®Google Scholar
• Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. doi:10.1016/j.jaad.2016.07.042
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128–1134. doi:10.1111/jdv.12768
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140. doi:10.1161/01.CIR.0000077913.60364.D2
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Trigoni A, Zouboulis CC. Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol. 2012;4(3):320–323. doi:10.4161/derm.23100
   PubMedGoogle Scholar
• Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27(5):622–627. doi:10.1111/j.1468-3083.2012.04500.x
   PubMed Web of Science ®Google Scholar
• Poizeau F, Nowak E, Kerbrat S, et al. Association between early severe cardiovascular events and the initiation of treatment with the anti–interleukin 12/23p40 antibody ustekinumab. JAMA Dermatol. 2020;156(11):1208–1215. doi:10.1001/jamadermatol.2020.2977
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Dommasch ED, Mehta NN. Association between early severe cardiovascular events and ustekinumab treatment? JAMA Dermatol. 2021;157(1):123. doi:10.1001/jamadermatol.2020.4456
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol. 2020;140(1):85–93.e2. doi:10.1016/j.jid.2019.07.679
   PubMed Web of Science ®Google Scholar
• Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–728. doi:10.1093/cvr/cvz009
   PubMed Web of Science ®Google Scholar
• Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circulation. 2020;13(9):e011199. doi:10.1161/CIRCIMAGING.120.011199
   PubMed Web of Science ®Google Scholar
• von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062. doi:10.1016/j.jid.2018.10.042
   PubMed Web of Science ®Google Scholar
• Makavos G, Ikonomidis I, Andreadou I, et al. Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis. Cana J Cardiol. 2020;36(1):100–111. doi:10.1016/j.cjca.2019.06.021
   PubMed Web of Science ®Google Scholar
• Marovt M, Marko P, Pirnat M, Ekart R. Effect of biologics targeting interleukin‐23/‐17 axis on subclinical atherosclerosis: results of a pilot study. Clin Exp Dermatol. 2020;45(5):560–564. doi:10.1111/ced.14180
   PubMed Web of Science ®Google Scholar
• Kaiser H, Näslund-Koch C, Kvist-Hansen A, Skov L. Does systemic anti-psoriatic treatment impact the risk of cardiovascular disease? A review over cardiovascular imaging studies. Dermatol Ther. 2024;14(2):303–321. doi:10.1007/s13555-024-01098-z
   Web of Science ®Google Scholar
• Al-Yafeai Z, Sondhi M, Vadlamudi K, et al. Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS). Int J Cardiol. 2024;402:131819. doi:10.1016/j.ijcard.2024.131819
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cantero A, Reddy AS, Dey AK, et al. Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. Eur J Prev Cardiol. 2022;29(4):591–598. doi:10.1093/eurjpc/zwaa033
   PubMed Web of Science ®Google Scholar
• Bardehle F, Sies K, Enk A, Rosenberger A, Fink C, Haenssle H. Nailfold videocapillaroscopy identifies microvascular pathologies in psoriasis vulgaris: results of a prospective controlled study. JDDG. 2021;19(12):1736–1744.
   Google Scholar
• Dey AK, Teague HL, Adamstein NH, et al. Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: findings from an observational cohort study. J Cardiovasc Comput Tomogr. 2021;15(4):372–379. doi:10.1016/j.jcct.2020.12.006
   PubMed Web of Science ®Google Scholar
• O’Hagan R, Gonzalez-Cantero A, Patel N, et al. Association of the triglyceride glucose index with insulin resistance and subclinical atherosclerosis in psoriasis: an observational cohort study. J Am Acad Dermatol. 2023;88(5):1131–1134. doi:10.1016/j.jaad.2022.08.027
   PubMed Web of Science ®Google Scholar
• Berna-Rico E, Abbad-Jaime de Aragon C, Ballester-Martinez A, et al. Monocyte-to-high-density lipoprotein ratio is associated with systemic inflammation, insulin resistance, and coronary subclinical atherosclerosis in psoriasis: results from 2 observational cohorts. J Invest Dermatol. 2024. doi:10.1016/j.jid.2024.02.015
   Google Scholar
• Daudén E, Castañeda S, Suárez C, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013;27(11):1387–1404. doi:10.1111/jdv.12024
   PubMed Web of Science ®Google Scholar
• Ford AR, Siegel M, Bagel J, et al. Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the national psoriasis foundation: a systematic review. JAMA Dermatol. 2018;154(8):934–950. doi:10.1001/jamadermatol.2018.1412
   PubMed Web of Science ®Google Scholar
• Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes. 2015;39(8):1197–1202. doi:10.1038/ijo.2015.64
   PubMed Web of Science ®Google Scholar
• Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175(5):402–413. doi:10.1093/aje/kwr325
   PubMed Web of Science ®Google Scholar
• Azdaki N, Salmani F, Kazemi T, et al. Which risk factor best predicts coronary artery disease using artificial neural network method? BMC Med Inform Decis Mak. 2024;24(1):52. doi:10.1186/s12911-024-02442-1
   PubMed Web of Science ®Google Scholar
• Tampa M, Sarbu MI, Mitran MI, Mitran CI, Matei C, Georgescu SR. The pathophysiological mechanisms and the quest for biomarkers in psoriasis, a stress-related skin disease. Dis Markers. 2018;2018:5823684. doi:10.1155/2018/5823684
   PubMed Web of Science ®Google Scholar
• Rao A, Kacker S, Saboo N. A study to evaluate the effect of a combined approach of yoga and diet in high-risk cardiovascular subjects. Int J Yoga. 2023;16(2):90–97. doi:10.4103/ijoy.ijoy_71_23
   PubMedGoogle Scholar
• Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of lipid-lowering statin therapy in patients with and without psoriasis. Clin Drug Investig. 2017;37(8):775–785. doi:10.1007/s40261-017-0533-0
   PubMed Web of Science ®Google Scholar
• Garshick MS, Drenkova K, Barrett TJ, et al. A randomized open-label clinical trial of lipid-lowering therapy in psoriasis to reduce vascular endothelial inflammation. J Invest Dermatol. 2022;142(6):1749–52.e4. doi:10.1016/j.jid.2021.07.190
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cantero A, Boehncke WH, De Sutter J, Zamorano JL, Lambert J, Puig L. Statins and psoriasis: position statement by the psoriasis task force of the European Academy of Dermatology and Venerology. J Eur Acad Dermatol Venereol. 2023;37(9):1697–1705. doi:10.1111/jdv.19191
   PubMedGoogle Scholar
• Zhao SS, Yiu ZZN, Barton A, Bowes J. Association of lipid-lowering drugs with risk of psoriasis: a Mendelian randomization study. JAMA Dermatol. 2023;159(3):275–280. doi:10.1001/jamadermatol.2022.6051
   PubMed Web of Science ®Google Scholar
• Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. doi:10.1007/s00125-017-4336-x
   PubMed Web of Science ®Google Scholar
• Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 2016;16(1):1–11. doi:10.1186/s12895-016-0049-y
   PubMedGoogle Scholar
• Tam HTX, Thuy LND, Vinh NM, Anh TN, Van BT. The combined use of metformin and methotrexate in psoriasis patients with metabolic syndrome. Dermatol Res Prac. 2022;2022:1–7. doi:10.1155/2022/9838867
   Web of Science ®Google Scholar
• Singh S, Bhansali A. Randomized placebo control study of metformin in psoriasis patients with metabolic syndrome (systemic treatment cohort). Indian J Endocrinol Metab. 2017;21(4):581. doi:10.4103/ijem.IJEM_46_17
   PubMedGoogle Scholar
• Liu X, Yu P, Xu Y, et al. Metformin induces tolerogenicity of dendritic cells by promoting metabolic reprogramming. Cell Mol Life Sci. 2023;80(10):283. doi:10.1007/s00018-023-04932-3
   PubMed Web of Science ®Google Scholar
• Huang Z, Li J, Chen H, Yu D, Sun S. The efficacy of metformin for the treatment of psoriasis: a meta-analysis study. Postepy Dermatol Alergol. 2023;40(5):606–610. doi:10.5114/ada.2023.130524
   PubMed Web of Science ®Google Scholar
• Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3). doi:10.1530/EDM-23-0017
   PubMedGoogle Scholar
• Reali E, Caliceti C, Lorenzini A, Rizzo P. The use of microbial modifying therapies to prevent psoriasis exacerbation and associated cardiovascular comorbidity. Inflammation. 2024;47(1):13–29. doi:10.1007/s10753-023-01915-1
   PubMed Web of Science ®Google Scholar
• Momin ES, Khan AA, Kashyap T, et al. The effects of probiotics on cholesterol levels in patients with metabolic syndrome: a systematic review. Cureus. 2023;15(4):e37567. doi:10.7759/cureus.37567
   PubMed Web of Science ®Google Scholar
• Leon Carrion S, Sutter CH, Sutter TR. Combined treatment with sodium butyrate and PD 153035 enhances keratinocyte differentiation. Exper Dermatol. 2014;23(3):211–214. doi:10.1111/exd.12333
   PubMed Web of Science ®Google Scholar
• Lolou V, Panayiotidis MI. Functional role of probiotics and prebiotics on skin health and disease. Fermentation. 2019;5(2):41. doi:10.3390/fermentation5020041
   Google Scholar
• Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022;18(3):233–244. doi:10.1080/1744666X.2022.2039630
   PubMed Web of Science ®Google Scholar
• Ingrassia JP, Maqsood MH, Gelfand JM, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(1):28–36. doi:10.1001/jamadermatol.2023.4090
   PubMed Web of Science ®Google Scholar
• Trovato E, Rubegni P, Prignano F. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome. Expert Opin Biol Ther. 2022;22(12):1443–1448. doi:10.1080/14712598.2022.2093106
   PubMed Web of Science ®Google Scholar
• Eder L, Harvey P, Chandran V, et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study. J Rheumatol. 2018;45(3):378–384. doi:10.3899/jrheum.170379
   PubMed Web of Science ®Google Scholar
• Barbieri JS, Beidas RS, Gondo GC, et al. Analysis of specialist and patient perspectives on strategies to improve cardiovascular disease prevention among persons with psoriatic disease. JAMA Dermatol. 2022;158(3):252–259. doi:10.1001/jamadermatol.2021.4467
   PubMed Web of Science ®Google Scholar
• Song WB, Garshick MS, Barbieri JS, et al. A care coordination model to prevent cardiovascular events in patients with psoriatic disease: a multicenter pilot study. J Invest Dermatol. 2024. doi:10.1016/j.jid.2023.12.008
   Google Scholar